Overview

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

Phase:

Phase 3

Details

Lead Sponsor:

Sunovion

Treatments:

Eszopiclone